Xeris Biopharma Holdings

XERS

Market cap $1.07B

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on April 1, 2026, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 304,975 shares of its common stock to 90 new employee(s) under Xeris' Inducement Equity Plan. Xeris' Inducement Equity.

Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript

The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Xeris Biopharma (XERS) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.03 per share a year ago.

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provides financial guidance for full year 2026. "Thanks to the entire Xeris organization, 2025 was a transformational year, marked by focused execution, record reven.

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) are falling Friday after the company announced a patent infringement lawsuit to protect its drug, Recorlev.

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that its subsidiaries, Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited, have filed a patent infringement lawsuit under the Hatch-Waxman Act related to Recorlev® (levoketoconazole) in the United States District Court for the District of New Jer.

Evaluate the expected performance of Xeris Biopharma (XERS) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full year 2025 financial results before the open of the U.S. financial markets on Monday, March 2, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to di.